Disturbing news that the EU may be eating our continental breakfast in the effort to make drug development more effective and efficient. Innomed, the European Platform on Innovative Medicines, is looking to hammer out a deal in which pharma companies and the EU kick in about $750 million a year over ten years towards process improvements in drug development and regulatory reforms. Meanwhile, back home we squabble about spending more to collect an increasing amount of paper about post market safety, shutting down PDUFA and imposing criminal penalities on companies that refuse to complete post market studies that most patients don't want to enroll in. At the same time, FDA has a grand total of 6 million for Critical path and its overall budget is cut in the House.
Note to all those who posture on stem cell funding. It won't do a damn bit of good if we have a 19th century drug development infrastructure for testing products based on such research.